The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-04 and is reviewed periodically as new material appears.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Chromosome analysis using a karyotype involves special stains that generate light and dark bands, allowing identification of each chromosome under a microscope. Fluorescence in situ hybridization (FISH) involves fluorescent labeling of probes that bind to specific DNA sequences, used for identifying aneuploidy, genomic deletions or duplications, characterizing chromosomal translocations and determining the origin of ring chromosomes. Chromosome painting is a technique that uses fluorescent probes specific for each chromosome to differentially label each chromosome. This technique is more often used in cancer cytogenetics, where complex chromosome rearrangements can occur. Array comparative genomic hybridization is a newer molecular technique that involves hybridization of an individual DNA sample to a glass slide or microarray chip containing molecular probes (ranging from large ~200kb bacterial artificial chromosomes to small oligonucleotides) that represent unique regions of the genome. This method is particularly sensitive for detection of genomic gains or losses across the genome but does not detect balanced translocations or distinguish the location of duplicated genetic material (for example, a tandem duplication versus an insertional duplication).
=== Isolation === Before the isotopes can be separated and a ratio can be determined, the desired component of the tissue must be isolated. Such components include collagen, carbonate and apatite. Each component requires different means of isolation, and methods must be further specialised to account for the varied levels of decay and contamination which may occur as a result of taphonomy. In the case of collagen, there are three main modes of isolation:
== History == The company (the Ranpak name standing for Random Packaging) traces its origins to a machine patented by George R. Johnson in 1970 that converted kraft paper into shock absorbing crinkled paper for use in cushioning auto-parts to prevent such items being damaged in shipment. Johnson, working with entrepreneur and engineer, Raymond Q. Armington, an inventor with several packing- and storage related patents to his name, incorporated the company in 1972. Armington became its chairman, a position he held until his death in 1993. In early 2002, David M. Gabrielsen was appointed president and CEO of Ranpak replacing Steven E. Armington, son of the co-founder. In December 1991 Ranpak opened its first foreign manufacturing center in Heerlen, Holland. The plant produced packing material and packing machines for the European market. Ranpak's acquisitions include:
==== Deep-frying ==== This method produces ready to eat tempeh products. A culinary oil with a high smoke point, such as rapeseed, soy, safflower, peanut, or coconut oil, is heated to 180 °C (350 °F) in the deep fryer. The tempeh is deep-fried until golden brown and crisp, and then cooled quickly in a sterile environment to be sealed in Pliofilm bags and stored in a cool, dry place. The shelf life of this product lasts around a week but can be extended if the tempeh is sun dried or oven dried prior to deep frying.
Even after the Meiji era when hybrid cattle were encouraged, there were still a considerable number of pure Wagyu cattle remaining in the Taisho era (1912–1926). As a policy for the improvement of Wagyu, efforts were made to eliminate negative characteristics of hybrid cattle as much as possible. Specifically, the elimination of sudare (tiger stripes), nori-kuchi (grayish-white lips), unagi-sen (different fur color on the dorsal line), white spots, etc. On the other hand, efforts were made to improve the physique and weight of both pure and improved Wagyu cattle, and from around the 1920s, the term "improved Wagyu" came to refer to all Wagyu cattle, including not only improved Wagyu but also pure Wagyu. Around 1919, the examination and registration of Wagyu began mainly in western Japan, and pedigrees and body types began to be registered. Nine breeds were registered: Tajima, Bisaku, Hiroshima, Bocho, Shimane, Inhaku, Bungo, Kumamoto, and Kagoshima. However, the examination and registration process was carried out by each prefecture, and the criteria for examination varied. Around 1925, the results of the improvements became visible: the negative characteristics of crossbreeding had almost disappeared from Wagyu cattle, their size and weight had increased, and improvements in hindquarters were clearly visible.
Sources: en.wikipedia.org
Testosterone can also be aromatized into estradiol (E2) to inhibit LH. E2 decreases pulse amplitude and responsiveness to GnRH from the hypothalamus onto the pituitary. Changes in LH and testosterone blood levels and pulse secretions are induced by changes in sexual arousal in human males.
== Forms of hair removal and methods == Depilation is the removal of the part of the hair above the surface of the skin. The most common form of depilation is shaving or trimming. Another option is the use of chemical depilatories, which work by breaking the disulfide bonds that link the protein chains that give hair its strength. Epilation is the removal of the entire hair, including the part below the skin. Methods include waxing, sugaring, epilators, lasers, threading, intense pulsed light or electrology. Hair is also sometimes removed by plucking with tweezers.
damage during implantation damage during (other) surgical procedures chemical degradation of the breast implant shell trauma (blunt trauma, penetrating trauma, blast trauma) mechanical pressure of traditional mammographic breast examination Silicone implant rupture can be evaluated using magnetic resonance imaging; from the long-term MRI data for single-lumen breast implants, the European literature about second generation silicone-gel breast implants (1970s design), reported silent device-rupture rates of 8–15 per cent at 10-years post-implantation (15–30% of the patients). Additionally, high-resolution ultrasound is another effective method of evaluating silicone implant integrity.
The metabolism of propionyl-CoA occurs in the mitochondria and requires Vitamin B12 (as adenosylcobalamin) to make succinyl-CoA. When the conversion of propionyl-CoA to succinyl-CoA in the mitochondria fails due to Vitamin B12 deficiency, elevated blood levels of methylmalonic acid (MMA) occur. Thus, elevated blood levels of homocysteine and MMA may both be indicators of vitamin B12 deficiency. Adenosylcobalamin is needed as cofactor in methylmalonyl-CoA mutase—MUT enzyme. Processing of cholesterol and protein gives propionyl-CoA that is converted to methylmalonyl-CoA, which is used by MUT enzyme to make succinyl-CoA. Vitamin B12 is needed to prevent anemia, since making porphyrin and heme in mitochondria for producing hemoglobin in red blood cells depends on succinyl-CoA made by vitamin B12.
== Research == Hong's research focuses on elucidating the structure, dynamics and mechanism of membrane proteins using ssNMR. She is particularly known for her in-depth study of the Matrix-2 (M2) proteins of influenza A viruses, which are responsible for all flu pandemics in history. M2 is an acid-activated proton channel and a membrane scission protein of the influenza virus. Hong's ssNMR studies have provided insights into the proton-conduction mechanism of this channel, by quantifying the proton transfer rates and equilibria between water and the proton-selective histidine residue. She showed that the antiviral drug amantadine inhibits proton conduction by direct occlusion of the channel pore. She determined the cholesterol-binding structure of the M2 protein, which sheds light on how cholesterol mediates M2's membrane scission function. In 2020 she determined both the influenza B M2 protein structure and the SARS-CoV-2 envelope protein structure, the latter in rapid response to COVID-19. The 1.5 Å BM2 structures in the closed and open states revealed different activation mechanisms of BM2 compared to influenza AM2. The 2.1 Å SARS-CoV-2 envelope protein structure forms the basis for antiviral drug design. Other membrane proteins that Hong's group has studied include β-hairpin antimicrobial peptides, channel-forming colicins, and viral fusion proteins. She determined the structure of the membrane toroidal pores formed by the antimicrobial peptide protegrin-1, which explained the membrane-disruptive mechanism of this peptide.
Sources: en.wikipedia.org
== Awards == Hackenberger has received numerous awards for his work, including the Heinz Maier-Leibnitz Prize of the German Research Foundation (2011), the ORCHEM Prize of the German Chemical Society (2012), the Zervas Award of the European Peptide Society (2018), the Breakthrough of the Year Award in the life sciences from the Falling Walls Foundation (2020), the Astra-Zeneca Award of the Royal Society of Chemistry (2023), the Xiaoyu Hu Memorial Award of the Chinese Peptide Society (2023), and the Max Bergmann Medal (2024).
== Background == Plants and animals alike both use small polypeptides for signaling in cell-to-cell communication. CLAVATA3/Embryo Surrounding Region-Related, also known as a plant peptide hormone, signaling is important for cell to cell signaling but also long distance communication. These two actions are especially important for plant cells because they are stationary and must perform cell expansion. In multicellular organisms, cell-to-cell communication has been found to be very crucial for many growth processes that occur inside the organism. The 12 or 13 amino acid polypeptides are the mature forms of the CLE proteins that are derived from the conserved CLE domains. More and more CLE genes are being identified with more research being conducted in this area. CLE genes have not only been found in seed plants but also in lycophytes, bryophytes, and green algae.
=== Eriq: The Bum Rapper === First aired 19 April 2009 Mayhem Miller helps Eriq's ex-girlfriend Linda, by putting him in the ring with MMA champion Jon "Man of Faith" Murphy. She is the first female victim to appear on Bully Beatdown. Eriq taps out five times in the first round and quits very shortly into the second round, claiming his shoulder popped out. The on-site doctor found no such injury, and Linda states that Eriq frequently uses a shoulder injury claim when he fears losing a fight. The information Mayhem provided from the doctor and the statement from Linda leave the audience knowing the high likelihood that Eriq 'punked out' with a fake injury. She won $10,000.
The most common fault associated with malolactic fermentation is its occurrence when it is not desired. This could be for a wine that is meant to be acidic and fruity (such as Riesling) or it could be a wine that was previously thought to have gone through MLF and bottled only to have malolactic fermentation commence in the bottle. The outcome of this "in-bottle" fermentation is often gassy, hazy wine that can be unpalatable to consumers. Improvement in sanitation and control of lactic acid bacteria in the winery can limit the occurrence of these faults. For early Vinho Verde producers, the slight effervesce that came from in-bottle malolactic fermentation was considered a distinguishing trait that consumers enjoyed in the wine. However, wineries had to market the wine in opaque bottles to mask the turbidity and sediment that the "in-bottle MLF" produced. Today, most Vinho Verde producers no longer follow this practice and instead complete malolactic fermentation prior to bottle with the slight sparkle being added by artificial carbonation. While not necessarily a fault, malolactic fermentation does have the potential of making a wine "protein unstable" due to the resulting change in pH which affects the solubility of proteins in wine. For this reason, protein fining and heat stability tests on wine usually take place after malolactic fermentation has run to completion.
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.